Reference : Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes.
Scientific journals : Article
Human health sciences : Pharmacy, pharmacology & toxicology
Human health sciences : Endocrinology, metabolism & nutrition
http://hdl.handle.net/2268/216140
Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes.
English
Scheen, André mailto [Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques >]
2017
Expert Review of Clinical Pharmacology
1-14
Yes (verified by ORBi)
International
1751-2433
1751-2441
England
[en] Combined therapy ; DPP-4 inhibitor ; SGLT2 inhibitor ; dapagliflozin ; fixed-dose combination ; saxagliptin ; type 2 diabetes
[en] INTRODUCTION: Saxagliptin (a dipeptidyl peptidase-4 inhibitor, DPP-4i) and dapagliflozin (a sodium-glucose cotransporter type 2 inhibitor, SGLT2i) improve glucose control in type 2 diabetes (T2D) through different potentially complementary mechanisms, thus offering the opportunity for a combined therapy. Area covered: The characteristics of the saxagliptin/dapagliflozin combination are analysed, focusing on: 1) pharmacokinetic and pharmacodynamic properties; 2) efficacy and safety in phase III trials with concurrent and sequential add-on therapy; and 3) potential use in clinical practice, including in special populations (cardiovascular disease, heart failure, chronic kidney disease, elderly). Expert commentary: Conclusions drawn from clinical trials investigating combination with the separate drugs are considered to apply to the fixed-dose combination (FDC) that demonstrates bioequivalence. Dual saxagliptin/dapagliflozin therapy is more potent than either monotherapy and can be used as an initial combination or a stepwise sequential approach. Dual therapy is generally well tolerated and may be used in special populations, with some limitations because of the presence of dapagliflozin. However, the latter may offer some advantages because of multiple effects attributed to SGLT2i. The best place of this dual combination for the management of T2D and the profile of patients who will make the most of this combined therapy remains to be defined.
http://hdl.handle.net/2268/216140
10.1080/17512433.2017.1389645

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
2017 expert review pharma Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes.pdfPublisher postprint1.46 MBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.